三生制药（股票代码：01530）于2026年5月6日向香港联交所提交截至2026年4月30日止的股份变动月报表。报告显示，公司于4月期间因行使购股权新增发行34,000股普通股，发行后已发行股本从上月的2,538,005,412股上升至2,538,039,412股。
根据公告，本月内公司并无进行股份购回、注销或库存股份的发行及转让活动，法定/注册股本亦维持不变，共计50,000,000,000股，面值每股0.00001美元，法定/注册股本总额为500,000美元。本月因购股权行使所取得资金为259,080港元。
月报显示，公司确认符合香港联交所对最低公众持股量的相关规定。该公告由公司秘书黎少娟签署。公司表示会继续严格遵守香港联交所《上市规则》及相关法律规定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.